Chromatin deregulation is an emerging hallmark of cancer. However, the extent of 26 epigenetic aberrations during tumorigenesis and their relationship with genetic 27 aberrations are poorly understood. Using ChIP-sequencing for enhancers (H3K27ac and 28 H3K4me1), promoters (H3K4me3), active transcription (H3K79me2) and polycomb 29 (H3K27me3) or heterochromatin (H3K9me3) repression we generated chromatin state 30 profiles in metastatic melanoma using 46 tumor samples and cell lines. We identified a 31 strong association of NRAS, but not BRAF mutations, with bivalent states harboring 32
Introduction 48
Melanoma is a deadly disease with an estimated 96,000 new cases each year 1-3 . While 49 targeted therapy and immunotherapy have become the standard of care with significant 50 improvement in clinical response, more than 7,000 patients still succumb to this disease 51 per year due to primary or acquired resistance 4,5 . Therefore, it is critical to gain a deeper 52 understanding of the disease biology to design more effective therapies. 53
Large scale efforts from consortiums such as The Cancer Genome Atlas (TCGA) 54 have provided deeper understanding of molecular aberrations in the disease 6-8 . These 55 studies identified critical somatic mutations in this disease that likely occur due to UV 56 exposure. Among these, somatic mutations in important bona fide oncogenes and tumor 57 suppressors, such as BRAF, NRAS, NF1, INK/ARF, PTEN and TP53, have been 58 demonstrated to be well-chronicled drivers of this malignancy 6-8 . One of the important 59 findings from these studies were genetic aberrations in several key epigenetic regulators 60 such as EZH2, IDH1/2, ARID2, KMT2C and KMT2D 6-8 . Many of these proteins are 61 enzymes that regulate covalent modifications of histones 7, [9] [10] [11] [12] [13] . Although recent studies 62 provide insight into the correlation of isolated histone marks, there are a myriad of 63 possible combinatorial patterns of histone modifications, and it is these combinatorial 64 states -not individual modifications -that dictate epigenetic status of associated genomic 65 loci [14] [15] [16] . These observations suggest that epigenetic alterations, including those in 66 histone modifications, may play important roles in melanomagenesis. Indeed, specific 67 functional roles have been assigned to some of these players as well as histone variants 68 such as macroH2A and H2A.z in melanomas 17, 18 . In addition, our previous study showed 69 alterations in specific chromatin states during transition from pre-malignant to malignant 70 phenotype in melanoma 19 . 71
These studies provide strong rationale for a systematic mapping of epigenome to 72 obtain comprehensive understanding of epigenetic elements that may act as driver events 73 in specific melanoma tumors. This concept has been epitomized by the DNA methylation 74 profiles in large number of tumors by the TCGA study which has provided key concepts 75 about roles of this important epigenomic mark in cancer progression 11 . For example, a 76 subset of cancer types are demonstrated to harbor hypermethylation phenotype, termed 77
CpG Island Methylation Phenotype, which associated with mutations in IDH1/2 genes 11 . 78
Chromatin state mapping in large number of tumors has the potential to identify similar 79 concepts 20 . Furthermore, several projects such as ENCODE and Roadmap Epigenomics 80 have cataloged extensive histone modification in normal human tissues and cell lines 81 which allows for identification of cancer specific alternations in chromatin states 21, 22 . Since 82 epigenetic aberrations are reversible by targeting of their enzyme regulators, the 83 chromatin mapping efforts are likely to identify potentially novel therapeutic strategy in 84 specific genetic context. For example, our previous study suggested that HDAC inhibitors 85 could be a good strategy to block pre-malignant to malignant transition in melanoma 19 . 86
In this study, we present a comprehensive chromatin state analysis of metastatic 87 melanoma in 46 tumor samples (profiled by TCGA) and cell lines (Profiled by Cancer Cell 88
Line Encyclopedia (CCLE) or internal efforts at MD Anderson) by performing ChIP-89 sequencing of 6 histone modification marks. Overall, investigation revealed a mechanism 90 in which alterations of distinct chromatin states, including bivalent and exceptionally wide 91
H3K4me3 and H3K27me3 domains, regulate key drivers of a mesenchymal/invasive 92 phenotype, a network of genes that includes master transcription factors and melanocyte-93 specific regulators. Together, this study encompasses the most complete description 94 regarding the epigenetic circuitry governing melanoma metastasis that can serve as an 95 important resource for advancing the understanding of the melanoma epigenome. This TCGA tumor cohort is inclusive of multiple melanoma subgroups 6 , including 139 mutation subtypes (BRAF, NRAS, WT), transcriptomic subtypes (Immune, Keratin, MITF-140 low) and DNA-methylation subtypes (CpG, Hypermethlyated, Hypomethylated, Normal). 141
Before comparing chromatin state data and molecular subtypes, we first ensured the 142 generated ChIP-seq profiles could be uniquely mapped to the specific donor through CNV 143 analysis. In 18 of 20 tumors, the CNV analysis from ChIP-seq data correlated with the 144 CNV classification from TCGA ( Supplementary Fig. 1c, d) . Projection of chromatin state 145 data using Multidimensional Scaling (MDS) analysis revealed chromatin state E13 146 (bivalent state containing high levels of H3K27me3 and H3K4me3 and modest 147 enrichment of H3K9me3) was able to separate NRAS-mutant melanoma tumors from 148 1e). Moreover, differential analysis of bivalent chromatin states (E12 and E13) between 150 mutational subtypes (BRAF vs NRAS vs WT) demonstrated NRAS-enrichment specific 151 to bivalent H3K27me3 high ( Fig. 1f-h and Supplementary Fig. 2a-c H3K27me3 peaks + H3K9me3 peaks (bivalent H3K4/H3K9/H3K27me3) in each 161 individual sample. Bivalent loci were further identified as "common" in tumors and cell 162 lines if they were present in ~50% of the samples in each subgroup (BRAF = 7/13, NRAS 163 = 2/4, WT = 2/3, MSTC = 5/10 and CCLE = 8/16). In accordance with our chromatin state 164 analysis, NRAS-mutants displayed the greatest number of bivalent H3K27me3 loci out of 165 all the subgroups whereas WT samples displayed the least number of bivalent loci ( Fig.  166 1i and Supplementary Fig. 2d ). Importantly, both the MSTC and CCLE subgroups also 167 displayed a large number of bivalent H3K27me3 loci that were shared with melanoma 168 tumors ( Fig. 1i, j and Supplementary Fig. 2e-g) , further suggesting these domains are 169 enriched in cancer cells and are not a product of tumor heterogeneity. 170
Bivalent domains are lost and gained on key mesenchymal genes in metastatic 172

melanoma. 173
In embryonic stem cells (ESCs), bivalent promoters mark critical lineage-specific genes 174 which gain or lose these modifications as cells differentiate towards a particular 175 phenotype 24, 25 . Previous studies have demonstrated various cancer-related genes (i.e. 176 CDKN2A) maintain or regain bivalent promoters in normal tissues, however their role in 177 cancer progression has yet to be described 26 . To this end, we first computed unique 178 bivalent loci (H3K4me3 and H3K27me3) in BRAF-mutant, NRAS-mutant and WT 179 samples by overlapping common peaks in each tumor subtype which further suggested 180 NRAS-mutants contained the highest number of bivalent loci ( Fig. 2a and Supplementary 181 Fig. 3a-c) . To determine how subtype-specific bivalent polycomb losses and gains 182 influence melanoma progression, we calculated the overlaps of bivalent sites from NRAS-183 and BRAF-mutants to those in primary melanocytes (Fig. 2b, c and Supplementary Fig.  184 3d, e). We focused primarily on the comparisons between NRAS-and BRAF-mutants as 185 most significant differences in bivalency were observed to occur between these 186 subgroups ( Fig. 1f-i) . We posited that removal of H3K27me3 mark from bivalent loci in 187 melanocytes would lead to transcriptionally 'active' loci in melanoma tumors and such loci 188
were termed under "bivalent losses" (Fig. 2d) . Similarly, gain of H3K27me3 mark on loci 189 (bivalent in tumors) that harbor only H3K4me3 in melanocytes will lead to transcriptional 190 repression which were termed as "bivalent gains" (Fig. 2d) . Determination of the gene 191 targets (within +/-10KB of each locus) and subsequent pathway enrichment analyses by 192 GSEA MSigDB tool identified critical melanoma-associated "hallmark pathways" within 193 each genetic subgroup ( Fig. 2e) . For example, in NRAS-mutants, losses of melanocyte-specific bivalency included genes associated with the "epithelial-mesenchymal transition" 195 and "KRAS-signaling up", while gains of tumor-specific bivalency included genes 196 associated with "KRAS-signaling down" and "apical junction" ( Fig. 2e and Supplementary 197 Table 2 ). Furthermore, RNA-seq analysis between NRAS-mutant (n = 81) and BRAF-198 mutant (n = 118) TCGA SKCM tumors confirmed "epithelial-mesenchymal transition" and 199 "KRAS-signaling up" signatures to be upregulated specifically in NRAS-mutant samples 200 ( Fig. 2f and Supplementary Table 3) , demonstrating an association between shifts in 201 bivalent domains and gene expression patterns within critical melanoma pathways. 202
Indeed, apart from obvious activation of RAS pathway genes, previous studies have 203 demonstrated importance of activation of mesenchymal drivers and phenotypes in 204 invasive behavior of metastatic melanoma and other malignancies 27-29 . 205 In order to identify important metastasis driver genes that are subjected to 206 epigenetic regulation, we focused on genes that do not harbor genetic changes in 207 cancers, which included key EMT transcription factors (EMT-TF) ZEB1, TWIST1, SNAI1 208 and CDH1 ( Fig. 2e and Supplementary Fig. 3f ). In response to activation of NRAS or 209 BRAF, the EMT-TF network undergoes a reorganization that includes activation of ZEB1 210 and TWIST1 along with the loss of CDH1. This phenomenon is accompanied with 211 increased invasion and correlates with poor prognosis in metastatic melanoma patients 28 . 212
We observed that ZEB1, TWIST1, and additionally SNAI1 and TGFBI are held in a 213 bivalent state in melanocytes and transition to an active state in metastatic melanoma 214 tumors, which occurs in a subtype specific manner ( Fig. 2g and Supplementary Fig. 3g ). 215 harbor H3K4me3 in melanocytes and gain repressive bivalency in both NRAS-mutant and 218 BRAF-mutant tumors subtypes ( Fig. 2i) . This transition to repressive bivalency is 219 associated with their downregulation (Fig. 2j) . Interestingly, ZEB1 and TWIST1 harbored 220 bivalent chromatin states in embryonic stem cells and germ-layer stem cells, but not in 221 mesenchymal stem cells where they are active ( Supplementary Fig. 4a-d) . Various other 222 tissues such as breast (TWIST1 and ZEB1 30,31 ), brain (TWIST1 and ZEB1), colon 223 (TWIST1), lung (TWIST1) and ovarian (TWIST1) normal tissues or cell lines 224 ( Supplementary Fig. 4a-d ) showed varying degree of bivalency which correlated well with 225 gene expression patterns demonstrating this "bivalent loss" mechanism can be expanded 226 to various other tissues. In addition to EMT-TF, we observed bivalent shifts on several 227
well-characterized drivers of melanoma metastasis, such as BMI1 32 , RNF2 33 , and CDK6 17 228 ( Supplementary Fig. 3i-k) , further strengthening the hypothesis that shifts in bivalent 229 domain can be a key epigenetic event during metastasis. 230 231
Melanocyte-specific bivalent genes transition to transcriptionally active broad 232
H3K4me3 in melanoma tumors. 233
While surveying the transitions of bivalent domains to a transcriptionally active state 234 through the genome, we observed two distinct types of H3K4me3 profiles present in many 235 of the samples. For example, the TWIST1 domain spanned well beyond the gene body 236 whereas the ZEB1 domain was localized within the promoter region ( Fig. 2g and 237
Supplemental Fig. 4a, b) . In contrast to typical H3K4me3 domains that are usually 200-238 1000bp long, broad H3K4me3 domains can span thousands of kilobases and have been 239 implicated in various cellular processes, including increased gene expression, enhancer activity and tumor-suppressor gene regulation [34] [35] [36] . Hence, we posited that some 241 important driver genes that lose bivalency in melanocytes may retain or gain different 242 types (broad or non-broad) of H3K4me3 domains in melanoma tumors. 243
Hence, we systematically identified broad H3K4me3 domains by computing the 244 overall width and density from MACS2 broad peaks in BRAF-mutant, NRAS-mutant and 245 WT tumors ( Fig. 3a-c) . Globally, NRAS-mutant and BRAF-mutant subtypes harbored the 246 largest number of broad H3K4me3 peaks, in some cases spanning >30kb in NRAS-247 tumors ( Fig. 3b) . Similarly, the top 1% broadest domains in these subtypes extended well 248 beyond the typical H3K4me3 domain (200-1000bp), with peaks reaching over 4kb in 249 10/17 the individual samples profiled (Fig. 3d) . In contrast, WT samples harbored much 250
shorter H3K4me3 domains with the widest peaks spanning around 15kb ( Fig. 3c) . Here, 251 the top 1% broadest peaks did not markedly extend beyond the typical H3K4me3 domain, 252 with only 1/3 samples harboring peaks over 4kb at this percentage cutoff ( Fig. 3d) . Based 253 on these observations and previous reports, broad domains were defined as peaks that 254 extended at least 4x (> 4kb; merge size = 1kb) beyond that of typical H3K4me3 domain 255 ( Fig. 3d and Supplementary Fig. 5a ). Using this method, we identified two distinct types 256 of H3K4me3 in melanoma tumors including broad domains (> 4kb) spanning outside of 257 the TSS (mean length = 12.3kb) and non-broad domains (< 4kb) localized within the 258 promoter region (mean length = 2.2kb) ( Fig. 3e-f and Supplementary Fig. 5b) . GSEA 259 analysis suggested occurrence of broad domains on genes regulating important biological 260 processes implicated in melanoma metastasis and tumorigenesis, such as "TNFA 261 signaling via NFKB" 37 , "WNT signaling" 38,39 , and Hedgehog signaling" 40-42 ( Fig. 3g- 
i and 262
Supplemental Table 4) , further suggesting a role for broad domains in melanoma metastasis. Additionally, important melanoma drivers such as NEAT1, MALAT1, MYC 264 and EVX1 harbored broad H3K4me3 domains in and around their gene bodies ( Fig. 3j) . 265
To identify the subsets of melanocyte-specific bivalent genes that transition to 266 transcriptionally active broad domains (and lose H3K27me3 in tumors), we further 267 overlapped genes that harbor 1) bivalent domains uniquely in melanocytes (but not in 268 tumors), 2) tumor-specific broad or non-broad H3K4me3 domains, 3) active transcription 269 mark H3K79me2 and 4) gene expression [using RNA-seq data from NRAS (n=81), BRAF 270 (n=118) and WT (n=38) metastatic samples]. Integrative analysis revealed NRAS-specific 271 broad domains were associated with increased gene expression ( Fig. 4a,b and 272
Supplemental Table 5 ) and enriched for melanoma pathways such as "UV response up", 273 "KRAS signaling up" and "Glycolysis" (Fig. 4c) . Genes displaying the transition to 274 transcriptionally active broad H3K3me3 included additional metastatic drivers known to 275 function in the switch to an mesenchymal/invasive state, including SOX9, POU3F2, 276 PDGFRA and MYCN (3.7kb width) ( Fig. 4d, f) , While we also identified a broad 277
H3K4me3-associated increase of transcription in WT samples, this occurred on a 278 markedly lower number of genes many of which were shared with NRAS samples ( Fig.  279 4a, b). In contrast to broad domains, we identified a relatively large and constant number 280 of genes transitioning from a bivalent state to non-broad H3K4me3 in melanoma tumors, 281 many of which were present within all mutational subtypes ( Fig. 4a) . On a global level, 282
we did not observe a change in the mean expression levels of melanocyte-specific 283 bivalent genes that transitioned to non-broad H3K4me3 domains in any melanoma 284 subtype ( Fig. 4b) , however, gene expression changes in specific genes were noted. 285
These included various genes known to be misregulated upon the aberrant activation of 286 RAS/RAF signaling, including VCAN as well as various RAS-effectors such as 287 RASGEF1B, RASEF, RASGRP1, RAPGEF5, and ARHGAP27 (Fig. 4e, g and 288 Supplementary Fig. 5c-e ), Overall, these results suggest that melanocyte-specific 289 bivalent losses that transition to broad H3K4me3 domains in NRAS-mutant tumors 290 regulate/increase the expression of mesenchymal/invasive drivers during metastatic 291 progression. 292 293 Broad H3K4me3 domain spreading is associated with increased transcriptional 294
activation. 295
Our results suggest that during the transition from a bivalent to an active state, genes that 296 retain broad H3K4me3 domains are associated with increased transcriptional activation 297 compared to non-broad domains in melanoma tumors ( Fig. 4a-c) . However, this was only 298 observed on a small subset of genes (NRAS = 97; Supplementary Table 5 ). We 299 considered that another mechanism of gene activation could be spreading of the 300 H3K4me3 signal, while gene repression may be associated with shortening of the broad 301 H3K4me3 domains. Indeed, a previous report demonstrated that H3K4me3 domain 302 shortening is associated with decreased gene expression of tumor suppressor genes in 303 lung and liver cancers 36 . Therefore, we investigated whether the size of H3K4me3 304 domains are altered in metastatic melanoma. First, on a genome-wide level, we observed 305 preferential shortening (< 2kb) of all H3K4me3 peaks in melanoma tumors relative to 306 melanocytes ( Fig. 5a) . Focusing on the promoter-associated broad H3K4me3 peaks (-307 /+10kb TSS), we further observed preferential shortening (< 2kb) of these peaks in 308 melanoma tumors which was associated with a decrease in gene expression levels (Fig. Table 6 ). Promoters harboring some of the broadest H3K4me3 310 domains displayed marked shortening on critical components of the melanocyte 311 regulatory network in melanoma tumors, including PMEL (aka GP100), MITF, ZEB2 and 312 TFAP2A 43 ( Fig. 5e and Supplementary Fig. 6a, b) . Because genes such as MITF and 313 ZEB2 are differentially expressed in alternate phenotypic states, displaying high 314 expression in melanocytes (or proliferative phenotype) and low expression in melanoma 315 tumors 28,44 ( Fig. 5f and Supplementary Fig. 6c) , this finding illustrates a new epigenetic 316 mechanism for their misregulation in metastatic melanoma. Similar to that of bivalent 317 losses, we also identified a smaller subset of promoters that gained broad H3K4me3 in 318 melanoma tumors. The top promoters displaying a broad H3K4me3 transition (> 10kb, 319 29 genes) were enriched for critical developmental regulators including DLX1/2, TBX3, 320 HMX2/3 and LBX1, many of which were also upregulated in metastatic melanoma tumors 321 and hence suggest potential oncogenic roles for these proteins (Fig. 5g, h and 322 Supplementary Fig. 6d, e ). Together, these results suggest broad H3K4me3 domains are 323 associated with higher expression that decreases upon shortening on key melanocyte-324 specific promoters during the transition to metastatic melanoma. 325 326 Broad H3K27me3 domains display preferential lengthening in metastatic 327
5b-d and Supplemental
melanoma. 328
Another possible transition of bivalent domains is the loss of H3K4me3 and retention or 329 extension of H3K27me3 domains. Therefore, we identified H3K27me3 domains by 330 computing overall width and density from MACS2 broad peaks in BRAF-mutant, NRAS-331 mutant and WT samples ( Supplementary Fig. 7a-c) . In all subtypes, we observed 332 exceptionally wide H3K27me3 domains spanning tens of thousands of kilobases with 333 multiple peaks extending well over 100kb in BRAF-and NRAS-mutant samples 334 ( Supplementary Fig. 7a-c) . Globally, the top 1% broadest H3K27me3 domains in 14/20 335 tumors extended well over 10kb ( Fig. 6a and Supplementary Fig. 7e ; merge size = 1kb). 336
In contrast to the results for H3K4me3, we observed preferential lengthening of 337 H3K27me3 domains on a global level (> 2kb) in BRAF-, NRAS-mutants and WT samples 338 ( Fig. 6b) . However, since H3K27me3 is already known as a broad mark, we focused on 339 promoter regions that displayed large extensions or constrictions (> 10kb) of H3K27me3 340 domains. Although we observed relatively consistent number of broad (> 4kb) 341
H3K27me3-associated promoters across mutational subtypes (Fig. 6c) , each subtype 342 displayed a different pattern of H3K27me3 in comparison to melanocytes, with NRAS-343 and BRAF-mutant samples displaying preferential lengthening and WT preferential 344 shortening (Fig. 6d) . Importantly, melanocytes harbored much shorter broad H3K27me3 345 domains (~50kb) compared to all tumors (Supplemental Fig. 7d) , While the largest 346 constriction of H3K27me3 was just over 50kb, the largest extension spanned over 100kb 347
in BRAF-and 85kb in NRAS-mutant samples (Supplemental Table 7 ), further indicating 348 polycomb domains are exceptionally broad in melanoma tumors. Overall, the widest 349
H3K27me3 domain lengthening observed was on the HOXC locus spanning 102.8kb in 350 BRAF samples (Fig. 6e) . Interestingly, as 3' HOX genes are known to be expressed first 351 during normal development, we observed H3K27me3 spreading specifically towards the 352 3' end of the HOXC cluster in melanoma tumors. This 5' -> 3' H3K27me3 spreading was 353 also observed on other HOX cluster genes (HOXB/HOXD) and further associated with 354 the downregulation of various 3' members relative to melanocytes (Fig. 6f-h and 355 Supplementary Fig. 7f, g) Our study describes an epigenetic program for reorganization of an interconnected 365 regulatory network encompassing EMT-TF, melanocyte master regulators and 366 mesenchymal/invasive genes as melanocytes progress to metastatic melanoma. Our 367 work provides three major advances regarding the role of the epigenome in melanoma 368 metastasis: 1) Specific genetic events such as BRAF or NRAS mutations may utilize 369 specific chromatin states to bring about transcriptional changes unique that genotype. 2) 370
Chromatin state switches involving bivalent domains mark master regulatory genes 371 associated with a metastatic phenotype, including the epithelial-to-mesenchymal 372 transition. 3) In addition to bivalent domain switches, contraction or extension of broad 373
H3K4me3 and H3K27me3 domains may be a key driver in the regulation of pro-metastatic 374
genes. In addition to these findings, the current study encompasses the most 375 comprehensive dataset from a large number of well-annotated samples which can help 376 the community better understand the epigenetic circuitry governing melanoma 377
metastasis. 378
Our results suggest that assimilation of epigenetic traits may be critical to evolution 379 of metastatic clones, consistent with some prior studies 17,45 . It has been argued that 380 evolution of cancer cells through metastasis entails constant acquisition and switching of 381 cellular phenotypes during its journey from the primary site to colonization in a distant 382 organ 46 . Hence, the molecular processes governing metastasis may mirror those driving 383 tissue differentiation during normal development. At the same time, those molecular traits 384 that allow establishment/evolution of neo-phenotypes, such as the ones in play during 385 selection of crossweinless phenotype observed by Waddington many decades ago 47 , 386 may also play an important driver role in evolution of cells undergoing metastasis. 387
Waddington's "genetic assimilation" model suggested that specific traits (genetic or 388 epigenetic) driving a cell towards a specific differentiation state in response to certain 389 environmental pressure are assimilated in the genome (or epigenome) during evolution. 390
Similarly, we propose that during evolution of cancer cells to metastasis, under selective 391 environmental pressure specific cell clones assimilate epigenetic traits -such as shifts in 392 bivalent and broad domains -in their genome which eventually help them disseminate 393 and colonize distant organs. 394
In ESCs, bivalent promoters mark critical lineage-specific genes which gain or lose 395 these modifications as cells differentiate towards a particular phenotype 24,25 . Moreover, 396 various cancer-related genes maintain or regain bivalent promoters in normal tissues 26 . 397
Here, we expand on those studies by demonstrating that bivalent domains are lost and 398 gained on critical EMT-TF, melanoma-specific drivers and mesenchymal genes as 399 melanocytes progress to metastatic melanoma. Shifts from bivalent states to active or 400 repressive marks are likely the least energy-intensive route to gene activation or 401 repression respectively (https://doi.org/10.1101/456525). Since metastasis involves 402 several cell fate transitions, which likely employ transcriptional circuitry consisting of 403 multiple genes, energetically the use of shifts involving bivalent chromatin states would 404 be favored as the preferred mode of gene regulation. It can be suggested that this specific 405 epigenetic process could constitute one of the primary 'forces' that can help with the 406 'canalization' (per Waddington model) of the pro-metastatic clones. 407
Interestingly, our study for the first time suggests that melanomas harbor 408 exceptionally wide H3K4me3 domains on key drivers of invasion and metastasis 409 (POU3F2 48,43 , SOX9 49 , PDGFRA 50 and PDGFA) and this transition was associated with 410 increased transcriptional activation. It is likely, barring physical and chemical barrier, that 411 addition of H3K4me3 marks on adjacent nucleosome may require less energy due to 412 already recruited methylation machinery, and hence may be a preferred mode for relative 413 increase in gene expression to meet the needs of metastatic cells. The observations of 414 broad domains on critical components of the melanocyte regulatory network, including 415 MITF 51,52 , ZEB2 28,44 , TFAP2A 43 and PMEL (aka GP100), as well as other genes not 416 known to be previously associated with melanoma, including MYCN, KLF6, NR2F2 and 417 CPEB2, may allow for identification of pro-metastatic drivers whose expression is 418 mediated by epigenetic events. Overall, our work identifies new principles of epigenome 419 regulation in melanoma metastasis and strengthens the hypothesis that metastatic 420 dissemination is likely driven by specific epigenetic events. 
Collection of melanoma tumor samples 455
Melanoma tumors were obtained from the Melcore tumor bank at MD Anderson Cancer 456
Center. 457
Characterization of melanoma short term cultures 458
Melanoma short term cultures were generated from metastatic tumor specimens as part 
Chromatin immunoprecipitation assays 484
ChIP assays were performed as described previously 56 . Briefly, ~2 × 107 cells were 485 harvested via cross-linking with 1% (wt/ vol) formaldehyde for 10 min at 37 °C with 486
shaking. After quenching with 150 mM glycine for 10 min at 37 °C with shaking, cells were 487 washed twice with ice-cold PBS and frozen at −80 °C for further processing. Cross-linked 488 pellets were thawed and lysed on ice for 30 min in ChIP harvest buffer (12 mM Tris-Cl, 1 489 × PBS, 6 mM EDTA, 0.5% SDS) with protease inhibitors (Sigma). Lysed cells were 490 sonicated with a Bioruptor (Diagenode) to obtain chromatin fragments (~200-500 bp) and 491 centrifuged at 15,000 × g for 15 min to obtain a soluble chromatin fraction. In parallel with 492 cellular lysis and sonication, antibodies (5 μg/3 × 106 cells) were coupled with 30 μl of 493 AMPure XP to retain fragments (~200-500 bp) and quantified using the Qubit 2000 and 510
Bioanalyzer 1000 before multiplexing. 511 512
ChIP-seq data processing 513
Raw fastq reads for all ChIP-seq experiments were processed using a snakemake based 514 pipeline 57 .
Briefly, raw reads were first processed using FastQC 515 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and uniquely mapped reads 516 were aligned to the hg19 reference genome using Bowtie version 1.1.2 58 . Duplicate reads 517 were removed using SAMBLASTER 59 before compression to bam files. To directly 518 compare ChIP-seq samples uniquely mapped reads for each mark were downsampled 519 per condition to 18 million, sorted and indexed using samtools version 1.5 60 . To visualize 520
ChIP-seq libraries on the IGV genome browser, we used deepTools version 2.4.0 61 to 521 generate bigWig files by scaling the bam files to reads per kilobase per million (RPKM). 522
Super ChIP-seq tracks were generated by merging bam files from each cancer type, 523 sorting and indexing using samtools and scaling to RPKM using deepTools. 524 525
Chromatin state calls 526
ChromHMM 62 was used to identify combinatorial chromatin state patterns based on the 527 histone modifications studied. Normalized bam files were converted to bed files and 528 binarized at a 1000bp resolution using the BinarizeBed command. We specified that 529
ChromHMM should learn a model based on 18 chromatin states. As we considered 530 models between 8 and 30 chromatin states, we chose an 18-state model because it is 531 large enough to identify important functional elements while still being small enough to 532 interpret easily. To determine chromatin state differences between different groups we 533 used a two-step process. First, using the segmentation calls from the ChromHMM output 534 the entire genome is divided into non-overlapping windows of 10 Kb. We next count the 535 number of times a chromatin state is observed in each of the 10 Kb windows and obtain 536 a frequency matrix for each state in the ChromHMM model (E1-E18). In the second step, 537 low variable genomic loci are removed from the frequency matrix and significant 538 differences between two groups of samples types are calculated by using a 539
nonparametric Mann Whitney Wilcoxon test with a P-value < 0.05 for each state 540 separately. 541 542 Correlation of copy number from ChIPseq and SNP array. 543 SKCM TCGA copynumber data were downloaded by TCGAbiolinks 63 . Copy number 544 analysis for ChIPseq was carried out using copywriteR 64 , which uses off-target reads for 545 accurate copy number detection. The ChIP-seq input files were used, which represent 546 low-pass whole genome sequencing data sets. Bin size of 200kb was used for analysis. 547
The copy number of each gene was determined by overlapping the genes with the 548 segmentation files from ChIPseq and SNP array, respectively. The Pearson correlation 549 of the copy number of all genes among samples was calculated and plotted in heatmap 
Identification of broad H3K4me3 and H3K27me3 domains 586
Broad H3K4me3 domains were identified using MACS2.1.0 with the broad setting (p-587 value of 1e-5) followed by merging adjacent peaks within 1kb using mergeBed 66, 69 . We 588 determined the optimal distance to merge adjacent peaks based on the number of broad 589
H3K4me3 and H3K27me3 domains at distance thresholds between 1kb through 10kb in 590 each mutational subtype. Broad H3K4me3 domains were further classified within the top 591 1% of the broadest peaks that extended at least 4x (>4kb) beyond that of a typical 592
H3K4me3 domain (0.2kb-1kb). Final peaksets for common sites broad and non-broad 593
H3K4me3 and H3K27me3 domains were defined as peaks present in ~50% of each 594 mutational subtype and melanocytes (NRAS = 2/4, BRAF = 7/13, WT = 2/3 and 595 Melanocytes = 2/2) as described in identification and visualization of ChIP-seq binding 596 sites. 597 598
Assigning binding sites to genes 599
A list of Ensembl genes was obtained from the UCSC Table browser 600 (http://genome.ucsc.edu/). Proximal promoters were defined as ±10kb from the 601 transcription start site (TSS) and genic regions were identified as +10kbTSS to the 602 transcription end site (TES). Peaks were assigned to genes if they overlapped the 603 promoter or genic region by a minimum of 1bp using intersectBed. Gene body heatmaps 604 and average density plots were generated using ngs.plot 70 . 605 606
Gene set enrichment analysis 607
Gene Set Enrichment Analysis (GSEA) was performed using GSEA/MSigDB 69 608 HALLMARK and KEGG pathways based on ensemble gene lists from peaks within -10kb-609 TES for bivalent domains and ±10kbTSS for broad H3K4me3 domains. All pathways are 610 significant based on FDR q-value. 611
612
RNA-sequencing data processing
For TCGA data, raw counts were obtained from TCGAbiolinks 63 in R 614 (http://www.rstudio.com/).and transformed to TPM. For Roadmap data, raw counts were 615 obtained from http://www.roadmapepigenomics.org/ and transformed to TPM. For all 616 RNA-seq boxplots, gene expression values from both datasets were normalized using 617 quantile normalization function in R. For identification of differentially expressed genes 618 and GSEA analysis between NRAS and BRAF melanoma tumors, raw counts were 619 obtained from TCGAbiolinks. DESeq2 71 was employed for normalization of differential 620 gene expression analysis. GSEA 69 was run on a ranked gene list using HALLMARK gene 621 sets with default settings. 622
Data and software availability 623
The ChIP and mRNA sequencing data have been deposited in the NCBI GEO BioProject 624 database with the following accession number GSE134043. 625
626
. 
Figure 3
Figure 3: Distribution of exceptionally wide broad H3K4me3 domains in metastatic melanoma a) Scatterplots of peak width (x-axis) and height (y-axis) from MACS2 broad peak calls (p-value 1e-5) for H3K4me3 in BRAF mutant tumors. b) Scatterplots of peak width (x-axis) and height (y-axis) from MACS2 broad peak calls (p-value 1e-5) for H3K4me3 in NRAS mutant tumors. c) Scatterplots of peak width (x-axis) and height (y-axis) from MACS2 broad peak calls (p-value 1e-5) for H3K4me3 in WT tumors. d) Quartile plot displaying peak length distribution based on percentage of broadest H3K4me3 domains in melanoma tumors. Black line denotes 4kb peak length. e) Average density profile displaying broad (>4kb) and non-broad (<4kb) H3K4me3 domains at 10kb to +10kb around TSS. f) Heatmap of H3K4me3 signal sorted by width at -10kb to +10kb around transcription start sites (TSS). g) Top significant MSigDB/GSEA HALLMARK pathways based on broad H3K4me3 domains within -/+10kbTSS of a gene in BRAF-mutant tumors. h) Top significant MSigDB/GSEA HALLMARK pathways based on broad H3K4me3 domains within -/+10kbTSS of a gene in NRAS-mutant tumors. i) Top significant MSigDB/GSEA HALLMARK pathways based on broad H3K4me3 domains within -/+10kbTSS of a gene in WT tumors. j) Genome browser view of ChIP-seq tracks for H3K4me3 on the MALAT1, NEAT1, MYC and EVX1 genes in melanocytes and melanoma mutational subtypes. 
